$7.55
4.91% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US00650F1093
Symbol
ADPT

Adaptive Biotechnologies Corp Stock price

$7.94
-0.16 1.98% 1M
+2.80 54.47% 6M
+1.95 32.44% YTD
+4.96 166.44% 1Y
-6.61 45.43% 3Y
-20.19 71.77% 5Y
-12.06 60.30% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.42 5.59%
ISIN
US00650F1093
Symbol
ADPT
Sector
Industry

Key metrics

Market capitalization $1.18b
Enterprise Value $1.18b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.59
P/S ratio (TTM) P/S ratio 6.59
P/B ratio (TTM) P/B ratio 5.79
Revenue growth (TTM) Revenue growth 5.10%
Revenue (TTM) Revenue $178.96m
EBIT (operating result TTM) EBIT $-154.38m
Free Cash Flow (TTM) Free Cash Flow $-98.88m
Cash position $222.29m
EPS (TTM) EPS $-1.09
P/E forward negative
P/S forward 5.55
EV/Sales forward 5.55
Short interest 8.18%
Show more

Is Adaptive Biotechnologies Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Adaptive Biotechnologies Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Adaptive Biotechnologies Corp forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Adaptive Biotechnologies Corp forecast:

Buy
88%
Hold
13%

Financial data from Adaptive Biotechnologies Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
179 179
5% 5%
100%
- Direct Costs 82 82
16% 16%
46%
97 97
33% 33%
54%
- Selling and Administrative Expenses 137 137
5% 5%
77%
- Research and Development Expense 94 94
7% 7%
53%
-135 -135
22% 22%
-76%
- Depreciation and Amortization 19 19
31% 31%
11%
EBIT (Operating Income) EBIT -154 -154
23% 23%
-86%
Net Profit -159 -159
29% 29%
-89%

In millions USD.

Don't miss a Thing! We will send you all news about Adaptive Biotechnologies Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adaptive Biotechnologies Corp Stock News

Neutral
GlobeNewsWire
23 days ago
Enhanced assay granted approval by New York State's Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) --  Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive imm...
Neutral
Seeking Alpha
about 2 months ago
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q4 2024 Results Conference Call February 11, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of IR & FP&A Chad Robins - CEO and Co-Founder Kyle Piskel - CFO Susan Bobulsky - Chief Commercial Officer Sharon Benzeno - Chief Commercial Officer of Immune Medicine Harlan Robins - Co-Founder & Chief Scientific Officer Conference Call P...
Neutral
GlobeNewsWire
about 2 months ago
SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2024.
More Adaptive Biotechnologies Corp News

Company Profile

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Head office United States
CEO Chad Robins
Employees 619
Founded 2009
Website www.adaptivebiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today